Methods: We conducted a 60-item survey adapted and modified from the 2014 CDC Checklist for Core Elements of Hospital AMS Programs. The survey was answered by one responsible clinician of the AMS activities in targeted hosp via email or Google forms between October 2014 and April 2015. Questions addressed leadership support, accountability and drug expertise, actions performed, tracking, reporting, and education on AMS. Data were summarized using descriptive statistics.
Results: Twenty-seven respondents from 10 LA hosp completed the survey. Teaching hosp were 18 (66.7%). Several hosp did not have formal written statement supporting AMS (11/27, 40.7%). Fourteen (51.9%) hosp reported no information technology tools or training support for their AMS programs. Pharmacists were the least frequent (37%) professionals in the AMS teams. In the cases (14.8%) in which AMS was not leaded by an infectious disease physician, microbiologists or epidemiologists were in charge. Nine (33.3%) hosp failed to have recommendations based on local susceptibility for treatment of common clinical conditions. Also, antibiotic time-out audits after 48 h were not performed in 17 (63%) hosp and pre-authorization of specific antimicrobials was not required in 7 (25.9%). Automatic alerts for duplicative therapy and automatic stop for antibiotic orders were not performed in 25 (93%) and 17 (63%) hosp, respectively. Only seven (25.9%) laboratories agreed to perform and report confirmatory testing for multidrug-resistant organisms. Fifteen (55.6%) hosp monitor antibiotic consumption by Defined Daily Dose and in 11 (40.7%) some kind of education on AMS was performed.
Conclusion: Our findings evidence that AMS activities are partially implemented in LA, especially because of the lack of multidisciplinary staff. Institutional support is required for further development and improvement of AMS programs.
J. S. Muñoz,
K. Escandón-Vargas, None
L. Bavestrello, None
R. Quiros, None
C. Hernandez, merck sharp & dohme: Consultant , Consulting fee
C. Pallares, merck sharp & dohme: Consultant , Consulting fee
M. V. Villegas, merck sharp & dohme: Consultant , Consulting fee and Research support
See more of: Poster Abstract Session